# Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6

> **NCT01433887** · PHASE3 · COMPLETED · sponsor: **Third Affiliated Hospital, Sun Yat-Sen University** · enrollment: 535 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** 48-weeks course
- **DRUG:** Ribavirin
- **DRUG:** Peginterferon alfa2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01433887
- **Lead sponsor:** Third Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 535 (ACTUAL)
- **Last updated:** 2014-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01433887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01433887, "Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01433887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*